Search for: All records

This paper examines the performance of Multimodal LLMs (MLLMs) in skilled production work, with a focus on welding. Using a novel data set of real-world and online weld images, annotated by a domain expert, we evaluate the performance of two state-of-the-art MLLMs in assessing weld acceptability across three contexts: RV & Marine, Aeronautical, and Farming. While both models perform better on online images, likely due to prior exposure or memorization, they also perform relatively well on unseen, real-world weld images. Additionally, we introduce WeldPrompt, a prompting strategy that combines Chain-of-Thought generation with in-context learning to mitigate hallucinations and improve reasoning. WeldPrompt improves model recall in certain contexts but exhibits inconsistent performance across others. These results underscore the limitations and potentials of MLLMs in high-stakes technical domains and highlight the importance of fine-tuning, domain-specific data, and more sophisticated prompting strategies to improve model reliability. The study opens avenues for further research into multimodal learning in industry applications. 

Abstract Gene therapy is a promising therapeutic approach for genetic and acquired diseases nowadays. Among DNA delivery vectors, recombinant adeno‐associated virus (rAAV) is one of the most effective and safest vectors used in commercial drugs and clinical trials. However, the current yield of rAAV biomanufacturing lags behind the necessary dosages for clinical and commercial use, which embodies a concentrated reflection of low productivity of rAAV from host cells, difficult scalability of the rAAV‐producing bioprocess, and high levels of impurities materialized during production. Those issues directly impact the price of gene therapy medicine in the market, limiting most patients’ access to gene therapy. In this context, the current practices and several critical challenges associated with rAAV gene therapy bioprocesses are reviewed, followed by a discussion of recent advances in rAAV‐mediated gene therapy and other therapeutic biological fields that could improve biomanufacturing if these advances are integrated effectively into the current systems. This review aims to provide the current state‐of‐the‐art technology and perspectives to enhance the productivity of rAAV while reducing impurities during production of rAAV.